ProNAi: Clinical Trial Update (ProNAi) - Jun 9, 2015 - “PNT2258 single-agent treatment results in significant, durable responses in recurrent or treatment refractory NHL (r/r NHL), including durable responses in all subjects with DLBCL”; “PNT 2258 is safe and well tolerated when administered to subjects with r/r NHL for dosing periods up to 18 months and longer”
P2 data • Non-Hodgkin's Lymphoma • Oncology
|